Chronic Refractory Cough Market

Market Overview: 

The 7 major chronic refractory cough markets reached a value of US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.74% during 2024-2034.

The chronic refractory cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic refractory cough (CRC) is a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The disease can significantly affect an individual's quality of life, causing sleep disturbances, fatigue, and social isolation. The main symptom of this illness includes a dry, irritated cough localized around the laryngeal area. Other common indications of CRC involve globus, dyspnea, dysphonia, dizziness, persistent chest pain, night sweats, and physical complications, such as urinary incontinence, fractured ribs, muscle strain, etc. The diagnosis of this condition typically requires the identification of a patient's clinical features, medical history, and physical exam. A blood workup and allergy test can be utilized to evaluate signs of infection or other environmental factors that could be causing underlying symptoms. The healthcare provider may also perform spirometry or pulmonary function tests, which help determine lung functionality by measuring airflow in and out of the lungs. Additionally, laryngeal examination using flexible nasendoscopy, that detects the existence of laryngeal lesions or atypical motor patterns contributing to disease symptoms and laryngeal discomfort, is recommended among patients.

The increasing incidences of respiratory tract disorders secondary to sensory nerve damage caused by viral infections, inflammation, allergic factors, etc., are primarily driving the chronic refractory cough market. Besides this, the rising prevalence of various associated risk factors, including smoking, acid reflux, asthma, exposure to irritants, etc., which can irritate the airways, is also bolstering the market growth. Furthermore, the widespread adoption of neuro-modulating agents, like gabapentin and amitriptyline, since they act on the heightened neural sensitization that is linked with the pathogenesis of CRC, is creating a positive outlook for the market. Apart from this, the escalating utilization of non-pharmacological interventions, such as cough-suppression physiotherapy and speech therapy in patients who have failed or not responded to conventional medicinal regimens, is also augmenting the market growth. Additionally, the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life, is further expected to drive the chronic refractory cough market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic refractory cough market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic refractory cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic refractory cough market in any manner.

Recent Developments:

• In July 2024, Seyltx, Inc. announced the findings of a study that examined real-world electronic health record (EHR) data to estimate the prevalence of refractory chronic cough in the adult population. Based on this information, the company believes it may improve enrollment in its Phase 2b clinical trial and better predict the economic potential of a product candidate.
• In December 2023, Merck announced that the United States FDA had issued a Complete Response Letter (CRL) on the company's New Drug Application (NDA) for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist in development for the treatment of refractory chronic cough or unexplained chronic cough (UCC) in adults.
• In November 2023, Trevi Therapeutics, Inc. announced the start of its Phase 2a RIVER clinical project, which will evaluate Haduvio in refractory chronic cough patients. The RIVER trial is a double-blind, randomized, placebo-controlled, two-period crossover research to assess Haduvio's safety and efficacy in reducing persistent cough in refractory chronic cough patients.

Key Highlights:

• Refractory chronic cough impacts up to 10 percent of persons worldwide.
• Chronic cough affects approximately 10% of adults across different populations.
• Chronic cough is more prevalent in Europe, America, and Australia (10-20%) compared to Asia (<5%).
• In Copenhagen, Denmark, the total prevalence of chronic cough was 4%, with 3% in never-smokers, 4% in past smokers, and 8% in current smokers.
• The prevalence of persistent cough in children ranges between 1.1% and 21.9%.

Drugs:

BLU-5937 is a highly selective P2X3 antagonist (>1500 fold) for human P2X3 receptors, which are implicated in chronic cough, has the potential to be an important treatment option for chronic cough and other hypersensitization-related disorders. The P2X3 receptor in the cough reflex pathway is a reasonable target for treating chronic cough, as validated in several clinical trials with different P2X3 antagonists.

Gefapixant is an experimental, non-narcotic, orally given, selective P2X3 receptor antagonist that may be used to treat refractory or unexplained chronic cough. Chemical stimuli, such as adenosine triphosphate (ATP), can be released by airway lining cells in response to airway inflammation, irritation, and mechanical stress/injury. The binding of extracellular ATP to P2X3 receptors on C fibers in the airway can be detected as a signal of possible injury, resulting in an action potential that may cause coughing. Inhibiting extracellular ATP binding to P2X3 receptors is hypothesized to diminish sensory nerve activation and, as a result, coughing.

S-600918 is a pharmacological molecule that selectively blocks P2X3 receptors associated with cough reflexes, potentially alleviating refractory or unexplained chronic coughs. A randomized, double-blind, placebo-controlled crossover research involved 31 patients with refractory/unexplained chronic cough lasting 6 months or more. S600918's efficacy and safety were studied after two weeks of once-daily dosing.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic refractory cough market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic refractory cough market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic refractory cough marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic refractory cough market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic refractory cough market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic refractory cough market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic refractory cough across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic refractory cough by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic refractory cough by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic refractory cough across the seven major markets?
• What is the size of the chronic refractory cough patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic refractory cough?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Refractory Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic refractory cough drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic refractory cough market?
• What are the key regulatory events related to the chronic refractory cough market?
• What is the structure of clinical trial landscape by status related to the chronic refractory cough market?
• What is the structure of clinical trial landscape by phase related to the chronic refractory cough market?
• What is the structure of clinical trial landscape by route of administration related to the chronic refractory cough market?